This $692,768 Project Grant was awarded on March 1, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research at Rhode Island Hospital, a division of Lifespan Corporation, to study endothelial cell dysfunction and anoikis resistance in pulmonary arterial hypertension (PAH). The research aims to leverage the hospital's "cell biopsy" method to characterize endothelial cell phenotypes and identify molecular mechanisms underlying anoikis resistance in PAH. The project will compare endothelial cell samples from PAH patients at different disease stages, as well as other pulmonary vascular conditions, to elucidate factors influencing endothelial cell dysfunction. The findings are expected to inform new therapeutic targets and a personalized drug screening approach for reversing anoikis resistance in PAH.
Generated 3/18/25, 2:55 AM